Cytotoxic drugs administered in the context of intravesical chemotherapy include mitomycin C (MMC), epirubicin ... MMC therapy • Decrease drug dilution with urine by requesting the patient ...

Table 1 Phenotypes observed when mitomycin C is added to a lysogen lineage ... site water dilutions compared to buffer dilutions. When dilution is used to derive estimates of lytic and lysogenic ...

Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...

How do you use mitomycin C? JOHN R. SAMPLES, MD: I tend to titrate mitomycin C to the status of the tissue and the conjunctiva. If the tissue is thick, bombarded over the years with BAK ...

As of September 1995, with a median follow-up of 138 months, a statistically significant benefit occurred in the mitomycin arms with respect to cause-specific survival (0.74 +/- 0.05 v 0.51 +/- 0.05; ...

UGN-103 is a next-generation novel mitomycin-based formulation. "Reaching this Phase 3 trial milestone for UGN-103 highlights our drive to innovate and bring forward cutting-edge treatments for ...

Mitomycin C chemoablation can provide nearly 4 years of response in initial responders to therapy. Mitomycin reverse thermal gel for low-grade upper tract urothelial carcinoma (UTUC) chemoablation ...

Mitomycin C can be a cost-effective alternative to BCG as intravesical treatment for intermediate-risk nonmuscle-invasive bladder cancer at a time when BCG is in short supply. Mitomycin C has ...

LISBON – A topical application of 0.02% mitomycin-C can help prevent corneal haze associated with PRK and improve visual acuity without side effects, according to one ophthalmologist.

Overall, 471 patients in Australia, New Zealand, and the United Kingdom with previously untreated, unresectable mCRC were randomly assigned to the following: capecitabine; capecitabine plus ...